NASDAQ: GNTAGenenta Science Spa Stock
$2.57-0.30 (-10.45%)
Updated Oct 31, 2025
GNTA Price
$2.57
Fair Value Price
$0.29
Market Cap
$49.21M
52 Week Low
$2.33
52 Week High
$10.00
P/E
-4.7x
P/B
3.49x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$10.24M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.78
Operating Cash Flow
-$11M
Beta
0.34
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GNTA Overview
Genenta Science S.p.A. is a clinical-stage biotechnology company developing hematopoietic stem cell gene therapies for the treatment of solid tumors. The company's lead product candidate is Temferon, in Phase 1/2a clinical trials for the treatment of glioblastoma multiforme in patients with an unmethylated MGMT gene promoter. Genenta Science was incorporated in 2014 and is headquartered in Milan, Italy.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GNTA's potential to beat the market
- GNTA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GNTA
RankedUnranked of 488
RankedUnranked of 488
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.65 | A | |
| $93.48 | A | |
| $14.66 | A |
Be the first to know about important GNTA news, forecast changes, insider trades & much more!
GNTA News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GNTA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GNTA ($2.57) is overvalued by 778.53% relative to our estimate of its Fair Value price of $0.29 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GNTA ($2.57) is not significantly undervalued (778.53%) relative to our estimate of its Fair Value price of $0.29 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GNTA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GNTA due diligence checks available for Premium users.
Valuation
GNTA fair value
Fair Value of GNTA stock based on Discounted Cash Flow (DCF)
Price
$2.57
Fair Value
$0.29
Overvalued by
778.53%
GNTA ($2.57) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GNTA ($2.57) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GNTA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GNTA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.7x
Industry
-9.17x
Market
41.65x
GNTA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.49x
Industry
4.99x
GNTA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GNTA's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
GNTA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$25.4M
Liabilities
$11.1M
Debt to equity
0.78
GNTA's short-term assets ($24.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GNTA's short-term assets ($24.41M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GNTA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
GNTA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GNTA vs Biotech Stocks
Genenta Science Spa Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.